Related Experiment Video
Updated: Apr 21, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Immune Checkpoint Inhibitor-Associated Hepatobiliary Toxicity: A Case of Concurrent Immune-Mediated Hepatitis and
Balakrishna Ravella1, Eswar Chand Gadde2, Sravani Lokineni3
1Department of Internal Medicine, OSF Health St. Mary Medical Center, Galesburg, IL.
Abstract:
Immune checkpoint inhibitors are associated with immune-related adverse events, including immune-mediated hepatitis, while acute acalculous cholecystitis remains exceedingly rare. We report a 52-year-old man with metastatic melanoma who developed concurrent grade 3 immune-mediated hepatitis and acute acalculous cholecystitis 2 weeks after combination ipilimumab-nivolumab therapy. He presented with right upper quadrant pain, jaundice, and marked transaminitis. Imaging showed gallbladder wall thickening with pericholecystic fluid without cholelithiasis, and alternative etiologies were excluded. The patient improved with conservative management without corticosteroids, with complete symptom resolution and biochemical normalization. This case highlights a rare dual hepatobiliary immune-related toxicity and the potential for conservative management in selected patients.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatic Drug Excretion: Influencing Factors
Drug toxicity: Idiosyncratic Reactions
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Hepatitis

